Home > Notice & News   
 
.    24 1/2
Subject
Hyundai Pharm, Tranexamic Acid Topical Form Patent Application Completed
Content

(2015-10-14) On 14th, Hyundai Pharm announces that they submitted foreign patent application for HTB-003 (TA topical), world’s first topical technology, on September 28th in 10 countries (U.S.A, Canada, Brazil, Mexico, Japan, china, India, Indonesia, Thailand, Vietnam). HTB-003 (TA topical) is a new topical chemical form indicated for melasma and freckles, and it is the world’s first topical tranexamic acid product with changes in its use and form.

Tranexamic acid, a plasmin inhibitor, is known to be effective in freckles treatment which inhibits growth of melanin formative cell, melanin pigment, or arachidonic acid. Also, HTB-003 (TA topical) uses Hyundai’s Transdermal Accelerating Technology which enables tranexamic acid to rapidly delivered into skin and sustain for a period of time. Not only that, it is known that

HTB-003(TA topical), as whitening management concept, is recognized with its value in improvement from cosmetics to a pharmaceutical grade product with its safety and efficacy much improved; it is expected its market to be much increased due to its uniqueness in dual use in monotherapy and surgery

Yeong Hak Kim, president of Hyundai Pharm, states that “With patent application submission, I believe it was a good opportunity for HTB-003 (TA topical) to be recognized, the world’s first topical formulation technology, value and its excellence. We plan to further improve this technology to develop much effective and safe freckles treatment.”

Date
2015-10-14
   
 
No.
Subject
Date
27
2015-11-09
2015-10-14
24
2015-09-02
23
2015-06-25
22
2015-05-12
21
2015-04-17
20
2015-03-26
19
2014-12-12
18
2014-12-05
17
2014-11-13
16
2014-08-19
15
2014-06-30
14
2014-06-05
13
2014-03-28
12
2014-02-18